Treatment of NRAS-mutant melanoma

Current Treatment Options in Oncology
Douglas B Johnson, Igor Puzanov

Abstract

NRAS mutations in codons 12, 13, and 61 arise in 15-20 % of all melanomas. These alterations have been associated with aggressive clinical behavior and a poor prognosis. Until recently, there has been a paucity of promising genetically targeted therapy approaches for NRAS-mutant melanoma (and RAS-mutant malignancies in general). MEK inhibitors, particularly binimetinib, have shown activity in this cohort. Based on pre-clinical and early clinical studies, combining MEK inhibitors with agents inhibiting the cell cycling and the PI3K-AKT pathway appears to provide additional benefit. In particular, a strategy of MEK inhibition and CDK4/6 inhibition is likely to be a viable treatment option in the future, and is the most promising genetically targeted treatment strategy for NRAS-mutant melanoma developed to date. In addition, immune-based therapies have shown increasing activity in advanced melanoma and may be particularly effective in those with NRAS mutations. Combination strategies of immune and targeted therapies may also play a role in the future although clinical trials testing these approaches are in early stages.

References

Sep 13, 1994·Proceedings of the National Academy of Sciences of the United States of America·N E KohlT J Lee
Mar 23, 1994·JAMA : the Journal of the American Medical Association·S A RosenbergD E White
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsS A Rosenberg
Sep 22, 2001·Journal of Immunotherapy·D J Schwartzentruber
Jun 5, 2003·Nature Reviews. Cancer·Marcos Malumbres, Mariano Barbacid
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemD Von Hoff
Oct 2, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S RaoP A Palmer
Oct 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John RinehartMark B Meyer
Feb 3, 2005·International Journal of Cancer. Journal International Du Cancer·Malihe EskandarpourJohan Hansson
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patricia M LorussoMark B Meyer
Nov 18, 2005·The New England Journal of Medicine·John A CurtinBoris C Bastian
Jul 18, 2006·Melanoma Research·Jenny N PoynterStephen B Gruber
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John A CurtinBoris C Bastian
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tammie C YehEli Wallace
Jun 23, 2007·Nature Reviews. Drug Discovery·Panagiotis A KonstantinopoulosAthanasios G Papavassiliou
Apr 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alex A AdjeiS Gail Eckhardt
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia M LoRussoAlejandro D Ricart
Mar 25, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric B HauraShirish M Gadgeel
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Dec 17, 2010·Nature Reviews. Cancer·Chad V PecotAnil K Sood
May 28, 2011·Pigment Cell & Melanoma Research·Bianca DevittGrant McArthur
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Oct 14, 2011·Nature Reviews. Cancer·Yuliya Pylayeva-GuptaDafna Bar-Sagi
Nov 4, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John M KirkwoodReinhard Dummer
Dec 2, 2011·Journal of Immunotherapy·Richard W JosephMichael A Davies
Jan 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter A PrietoGiao Q Phan
Feb 7, 2012·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Harkanwal HalaitH Jeffrey Lawrence
Feb 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yingjun SuAnn Richmond
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 6, 2012·The New England Journal of Medicine·Keith T FlahertyUNKNOWN METRIC Study Group
Jul 24, 2012·Cell·Eran HodisLynda Chin
Jul 31, 2012·Nature Genetics·Michael KrauthammerRuth Halaban
Oct 2, 2012·The New England Journal of Medicine·Keith T FlahertyJeffrey Weber
Dec 12, 2012·Journal of Translational Medicine·Thomas F GajewskiUNKNOWN Cancer and Leukemia Group B

❮ Previous
Next ❯

Citations

Dec 1, 2015·Critical Reviews in Oncology/hematology·Ryan J DaveyNikola A Bowden
Sep 4, 2015·The Journal of Investigative Dermatology·Arnaud UguenMarc De Braekeleer
Apr 6, 2016·Future Oncology·Kimberly M KomatsubaraRichard D Carvajal
Jan 26, 2016·Chemical Biology & Drug Design·Yao-Yao YangFeng Qian
Mar 30, 2017·International Journal of Molecular Sciences·Georg RichtigMartin Pichler
Mar 31, 2017·Virchows Archiv : an International Journal of Pathology·C MelisJoost J van den Oord
Jul 15, 2017·International Journal of Molecular Sciences·Xian Yang ChanTerrence J Piva
Sep 2, 2017·American Journal of Clinical Dermatology·Alice Y Zhou, Douglas B Johnson
Aug 30, 2017·Mediators of Inflammation·Carmen Rodríguez-CerdeiraRoberto Arenas Guzman
Jan 20, 2018·BioMed Research International·Xiaohua WanZhongwu Li
May 23, 2018·Melanoma Management·Ileabett M Echevarría-Vargas, Jessie Villanueva
Feb 26, 2019·Melanoma Research·Deena M MaurerLazar Vujanovic
Mar 7, 2018·Molecular Systems Biology·Alireza AzimiGianluca Maddalo
Aug 12, 2017·Melanoma Research·Patrick GladfelterShaker A Mousa
Mar 4, 2020·International Journal of Oncology·Zhen DongHongjuan Cui
Jan 9, 2016·Current Oncology Reports·Romany A N JohnpulleJeffrey A Sosman
Apr 14, 2018·EMBO Molecular Medicine·Ileabett M Echevarría-VargasJessie Villanueva
Jul 17, 2018·Journal of Cancer Research and Clinical Oncology·Susan KennedyAnnemarie Larkin
Aug 16, 2019·Science Translational Medicine·Anna E VilgelmAnn Richmond
May 26, 2017·Cancer·Bobby Y ReddyHensin Tsao
Nov 22, 2018·Melanoma Management·Helen Tyrrell, Miranda Payne
Aug 14, 2019·Pigment Cell & Melanoma Research·Elisa BertoliAlessandro Marco Minisini
Aug 11, 2020·BioMed Research International·Luz D Gutiérrez-CastañedaJose D Tovar-Parra
Apr 23, 2016·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Yun XiaJiaming Sun
Jun 28, 2018·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·F SharoufM I Bhatti
Apr 27, 2018·Oncogene·Patricia Reyes-UribeJessie Villanueva
Jun 28, 2018·Frontiers in Oncology·Hildur HelgadottirAda Girnita
Apr 3, 2019·International Journal of Molecular Sciences·Paola SavoiaOttavio Cremona
Mar 1, 2016·Melanoma Management·Russell W Jenkins, Ryan J Sullivan
Jun 21, 2019·Medicinal Research Reviews·Daniela TomaselliAntonello Mai
Dec 8, 2020·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Charles-Antoine AssenmacherEnrico Radaelli
Dec 15, 2015·Cancer Discovery·Charles J SherrGeoffrey I Shapiro
Nov 10, 2020·Melanoma Research·Trevor S AndersonDevin B Lowe
Aug 24, 2018·Molecular Cancer Therapeutics·Marilia TakadaVilma Yuzbasiyan-Gurkan

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Related Papers

Current Treatment Options in Oncology
Douglas B Johnson, Jeffrey A Sosman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Kadoaki OhashiWilliam Pao
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
R GutzmerFür Komitee Kutane Nebenwirkungen Ado der das Ado
© 2021 Meta ULC. All rights reserved